Alixorexton, an investigational, oral, selective orexin 2 receptor agonist, demonstrated meaningful improvements across the trial’s dual primary endpoints of change from baseline in Maintenance of ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

Medical research has long sought to gloss over the hormonal and chromosomal complications typical of female biology. But embracing this complexity could benefit everyone ...

Skin cancer impacts millions of Americans annually, but your chances of getting skin cancer and when it is diagnosed depend ...

The modern world runs on data. Every click, purchase, diagnosis, and interaction feeds massive systems that shape our reality ...

The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.

Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With ...

The Head and Neck Cancer Drugs/Therapeutics Market is experiencing substantial growth, valued at USD 4.2 Billion in 2024 and projected to reach USD 8.5 Billion by 2033. This expansion reflects ...

The Acute Kidney Injury Treatment Market is set to witness robust growth from USD 2,540.5 million in 2025 to USD 5,289.5 ...

Patients with ankylosing spondylitis (AS) may require biological therapy, particularly tumour necrosis factor (TNF) inhibitors, which are effective but increase the risk of tuberculosis (TB).

The global bare metal cloud market size is projected to reach USD 52.66 billion by 2033, growing at a CAGR of 20.7% from 2025 ...

RIT Assistant Professor Stefan Schulze’s lab is working toward new biomedical treatment approaches through NIH research in ...